An international randomized double-blind placebo-controlled trial of anti-influenza hyperimmune intravenous immunoglobulin (IVIG) in individuals hospitalized with influenza (flu) A or B. 
The primary objective was to determine whether, when added to standard of care (SOC) treatment, IVIG helps reduce the severity and duration of flu symptoms. 
FLU-IVIG enrolled 313 participants at 33 sites in the US, Mexico, Europe, South America, and Australasia.
The study closed to enrollment on 1 June 2018.

FLU-IVIG EudraCT number: 2014-004271-22

For further details about the Influenza studies, please go to ClinicalTrials.gov and the Clinical Trials Register.